Skip to main content
. 2011 Jul 3;79(3):569–581. doi: 10.3797/scipharm.1104-18

Fig. 2.

Fig. 2.

Half-normal probability plot for the effects estimated in Plackett-Burman design (from Table 2) with the identification of margin of error (ME). Variable: % of binding of nimotuzumab evaluated by flow cytometry on A 431 (A) and H125 (B) cell lines respectively.